Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
about
Diagnostic Tests to Support Late-Stage Control Programs for Schistosomiasis and Soil-Transmitted HelminthiasesExpanding Praziquantel (PZQ) Access beyond Mass Drug Administration Programs: Paving a Way Forward for a Pediatric PZQ Formulation for SchistosomiasisPutting the treatment of paediatric schistosomiasis into context.Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies.The evolving schistosomiasis agenda 2007-2017-Why we are moving beyond morbidity control toward elimination of transmission.Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trialPraziquantel decreases fecundity in Schistosoma mansoni adult worms that survive treatment: evidence from a laboratory life-history trade-offs selection study.In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium.Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target.Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.Assessing the benefits of five years of different approaches to treatment of urogenital schistosomiasis: A SCORE project in Northern Mozambique.Cognitive deficits and educational loss in children with schistosome infection-A systematic review and meta-analysis.The effects of subcurative praziquantel treatment on life-history traits and trade-offs in drug-resistant Schistosoma mansoni.When Should the Emphasis on Schistosomiasis Control Move to Elimination?
P2860
Q28068274-63AB57F9-EF82-4CD6-AC05-CC1B20C74B04Q28554319-C31497CA-3C5F-4F8F-8FCE-3FBE25B4D794Q30234902-E301C4CC-C0DB-4726-BCF6-1BC5D5BDD5C4Q30378695-2CC2CBAC-09D2-48F4-9CED-C17117BCD193Q33584679-EE537156-5ED4-41D2-A9CA-E3562BD65191Q33800953-92D8507F-7235-4462-B840-F0D9665C5771Q33805145-D0B08120-4F2A-4CE9-BBAA-5B47934262E2Q38648427-0DD1D3BD-0F8B-42FA-90F5-B3560641F009Q39188232-B249FF38-D626-4A97-A289-22282CF377C1Q42369648-023620CE-D519-458E-8BBA-19823C92E1E8Q46598931-55CDC2CC-9EA6-4119-80E6-F65B11648E9CQ48252966-850D36C0-8B67-4283-A5AC-E941E54F9EFFQ52325706-7DCC2B1B-C0B0-400C-A6ED-A11D39197635Q57133725-159D0E60-7317-40E7-A438-58B77AFE31F8
P2860
Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Population Pharmacokinetics an ...... Required for Maximal Efficacy.
@ast
Population Pharmacokinetics an ...... Required for Maximal Efficacy.
@en
type
label
Population Pharmacokinetics an ...... Required for Maximal Efficacy.
@ast
Population Pharmacokinetics an ...... Required for Maximal Efficacy.
@en
prefLabel
Population Pharmacokinetics an ...... Required for Maximal Efficacy.
@ast
Population Pharmacokinetics an ...... Required for Maximal Efficacy.
@en
P2093
P2860
P50
P356
P1433
P1476
Population Pharmacokinetics an ...... Required for Maximal Efficacy
@en
P2093
Aaron Atuhaire
David Waterhouse
Govert J Van Dam
Janet T Scott
Jose C de Sousa-Figueiredo
Narcis B Kabatereine
Stephen Ward
P2860
P356
10.1128/MBIO.00227-16
P577
2016-08-09T00:00:00Z